TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03628872

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scaling and root planing
Description: A non-surgical procedure that treats periodontal disease, sometimes called a deep cleaning, is considered the gold standard (standard of care) of treatment for patients with chronic periodontitis.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scaling and root planing
Description: A non-surgical procedure that treats periodontal disease, sometimes called a deep cleaning, is considered the gold standard (standard of care) of treatment for patients with chronic periodontitis.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Er:YAG Laser
Description: This laser is intended to be used for dental surgery. The Er:YAG Laser emits an infrared beam which is readily absorbed by water contained by both hard and soft tissues of the human body. As a result, energy of the laser beam instantly vaporizes the water molecules in soft and hard tissues of the tooth and surrounding tissues causing the tissues to crumble away or resection of the soft tissues of gingival.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hand instruments
Description: 11/12 and 13/14 gracey, 4R/4L curette and sickle - standard of care choices for performing scaling and root planing.
Study: NCT05005923

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-surgically performed scaling and root planing
Description: Treatment of patients with periodontitis was performed using manual and ultrasonic instruments.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-surgically performed scaling and root planing
Description: Treatment of patients with periodontitis was performed using manual and ultrasonic instruments.
Study: NCT01102881

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glucose polymer fiber
Description: 20 grams of fiber per day split into two 10 gram doses administered as a breakfast cereal and a muffin or no-fiber breakfast cereal and muffin

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fiber made from corn starch
Description: 20 grams of fiber per day split into two 10 gram doses administered as a breakfast cereal and a muffin or no-fiber breakfast cereal and muffin

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: low fiber breakfast cereal and muffin
Study: NCT04246281

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SPRINT Peripheral Nerve Stimulation (PNS) System
Description: The SPRINT System delivers mild electrical stimulation to the nerves in your low back. The SPRINT System includes up to two leads (small wires) that are placed through your skin into your low back. The leads attach to devices worn on your body that deliver stimulation (called Stimulators).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard interventional management of low back pain
Description: Your doctor will determine which procedure or intervention is appropriate for your back pain. You may receive radiofrequency ablation, spinal cord stimulation, surgery, or another procedure or treatment, as appropriate.
Study: NCT03447015

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ambulation
Description: Ambulation during labour here will refer to moving from place to place during the first stage of labour that reduces the amount of time a woman spends laying down during this stage (measured by recording the number of minutes spend on walking).
Study: NCT01796899

Intervention type: OTHER
Group type: OTHER
Intervention: Brivaracetam 10 mg oral tablet

Intervention type: OTHER
Group type: OTHER
Intervention: Brivaracetam 50 mg oral tablet
Study: NCT03142737

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Red kidney bean intake
Description: Each participant will consume 1/2 cup of cooked red kidney bean

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eggs intake
Description: Each participant will consume 2 cooked large eggs.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peanut butter intake
Description: Each participant will consume 2 tablespoons of peanut butter.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ground beef intake
Description: Each participant will consume 2 ounces of 90% lean ground beef.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intact beef intake
Description: Each participant will consume 2 ounces of intact beef.
Study: NCT03098160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evofosfamide
Description: Evofosfamide given on day one and in combination with Ipilimumab on day 8 of the first two cycles, Ipilimumab given alone on day 8 of last two cycles for a total of four 21 day dosing cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Evofosfamide given on day one and in combination with Ipilimumab on day 8 of the first two cycles, Ipilimumab given alone on day 8 of last two cycles for a total of four 21 day dosing cycles.
Study: NCT02440464

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic HSCT
Description: Eligible patients with a Human Leukocyte Antigen (HLA)-matched related or unrelated donor will undergo allogeneic hematopoietic stem cell transplant at Day 0. For GVHD prophylaxis, patients will be given Tacrolimus from Day -3 until at least 6 months following initiation, at an intravenous daily dose of 0.015 mg/kg. This will be combined with an intravenous administration of Methotrexate at 5 mg/m2 on Days +1, +3, +6, and +11.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Allogeneic HSCT
Description: Eligible patients with a Human Leukocyte Antigen (HLA)-matched related or unrelated donor will undergo allogeneic hematopoietic stem cell transplant at Day 0. For GVHD prophylaxis, patients will be given Tacrolimus from Day -3 until at least 6 months following initiation, at an intravenous daily dose of 0.015 mg/kg. This will be combined with an intravenous administration of Methotrexate at 5 mg/m2 on Days +1, +3, +6, and +11.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Patients will receive conditioning treatment before and after HSCT. Fludarabine will be given at 30 mg/m2 intravenously on Day -6 through Day -3.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fludarabine
Description: Patients will receive conditioning treatment before and after HSCT. Fludarabine will be given at 30 mg/m2 intravenously on Day -6 through Day -3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Melphalan will be given at 70 mg/m2 intravenously on Days -4 and -3.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Melphalan
Description: Melphalan will be given at 70 mg/m2 intravenously on Days -4 and -3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib will be administered at 1.3 mg/m2 intravenously on Day -3.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bortezomib
Description: Bortezomib will be administered at 1.3 mg/m2 intravenously on Day -3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Between 60 and 120 days following HSCT, patients randomized to the experimental arm will receive Ixazomib maintenance. Maintenance will begin at 3-mg oral doses on Days 1, 8, and 15 of a 28-day cycle. This will increase to 4-mg doses on the same cycle schedule, following successful completion of 3 cycles at the previous dosage, for a total of 12 cycles.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Between 60 and 120 days following HSCT, patients randomized to the control group will be given 3 mg of placebo orally on Days 1, 8, and 15 of a 28-day cycle. This will increase to 4-mg doses on the same cycle schedule following successful completion of 3 cycles of placebo maintenance at the 3-mg dose. This will continue for a total of 12 cycles.
Study: NCT01796899

Intervention type: OTHER
Group type: OTHER
Intervention: Brivaracetam 75 mg oral tablet

Intervention type: OTHER
Group type: OTHER
Intervention: Brivaracetam 100 mg oral tablet

Intervention type: OTHER
Group type: OTHER
Intervention: 10 mL of Brivaracetam intravenous bolus injection (10 mg/mL)
Study: NCT03925675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PET/CT with F-Fluciclovine (Axumin)
Description: Comparison between PET/CT, MRI / MRS imaging, and biopsy histopathology. Data from each modality will be analyzed separately as described above to determine tumor recurrence and/or presence of radiation changes. Different metabolic profiles measured in areas of imaging changes and depicted by PET imaging will be characterized. Biopsy locations from stereotactic MRI data will be co-localized with PET/CT and MRSI to correlate biopsy histopathology with MRI+, MRSI+ and PET+ lesion data.
Study: NCT02327923

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Description: 50 mcg/kg for reversal of residual neuromuscular blockade

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Description: 50 mcg/kg for reversal of residual neuromuscular blockade

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glycopyrrolate
Description: 10 mcg/kg with neostigmine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glycopyrrolate
Description: 10 mcg/kg with neostigmine
Study: NCT01527188

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 100IR
Description: 100IR sublingual tablet of

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 300IR
Description: 300IR sublingual tablets of
Study: NCT03799341

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prize-Based Contingency Management
Description: Participants assigned to Prize-based Contingency~Management (PBCM) conditions will receive PBCM as an adjunct to TAU. PBCM will involve twice weekly one-on-one sessions with a provider for 12-weeks. During each session, a urine specimen provided by the patient will be tested for cocaine using a point-of-care dip-test. Results of point-of-care testing will be shared with the patient and negative results will be reinforced with draws from a fish bowl containing 500 paper slips, 250 of which award small, large, or jumbo prizes (remaining slips deliver words of encouragement). Patients will be reinforced with a single prize draw for their first negative specimen; an additional prize draw will be added for each consecutive negative result (up to 8~prize draws per session). Abstinence-contingent prize draws will be reset to one upon either a positive test result or unexcused, missed appointment.
Study: NCT01527188

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 500IR
Description: 500IR sublingual tablet of

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo sublingual tablet of
Study: NCT03678155

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pain app
Description: Pain Monitor app has been developed by a multidisciplinary pain expert panel, including physicians, psychologists, and nurses. Content has been validated in a previous study and usability has been shown to be excellent.
Study: NCT03678155

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pain app
Description: Pain Monitor app has been developed by a multidisciplinary pain expert panel, including physicians, psychologists, and nurses. Content has been validated in a previous study and usability has been shown to be excellent.
Study: NCT02829593

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: hypoglycemia (low blood sugar) and MRI
Description: hypoglycemia (low blood sugar) and MRI

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hypoglycemia (low blood sugar) and MRI
Description: hypoglycemia (low blood sugar) and MRI
Study: NCT02310139

Intervention type: PROCEDURE
Intervention: Colonoscopy
Study: NCT03489395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edoxaban
Description: Edoxaban 60 mg once a day for 4 weeks. Edoxaban 30 mg/day in patients with body weight ≤60 kg, or with concomitant therapy with verapamil/quinidine/dronedarone.
Study: NCT02188238

Intervention type: OTHER
Intervention: Saliva Sample Collection
Description: Saliva samples will be collected from healthy volunteers recruited locally. Stimulated whole mouth saliva is collected through stimulation by inert gum, and collecting the saliva by gently spitting into a sterile tube.
Study: NCT01120431

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral rehydration fluid
Description: Oral electrolyte solution or other clinically acceptable oral rehydration fluid, 5 to 10 mL of offered with encouragement every 5 to 10 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotonic hydration fluid and recombinant human hyaluronidase
Description: Single subcutaneous dose of 150 U recombinant human hyaluronidase, followed by infusion pump-delivered subcutaneous isotonic hydration fluid
Study: NCT00854581

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEG-interferon alfa-2b
Description: Administered subcutaneously.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEG-interferon alfa-2b
Description: Administered subcutaneously.
Study: NCT03799341

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment As Usual Outpatient Substance Use Treatment
Description: All participants will receive treatment as usual outpatient substance use services during the 12-week treatment interval. TAU will specifically entail recommended participation in at least two outpatient group and/or individual psychotherapy encounters per week within the Center for Treatment of Addictive Disorders (CTAD) at VA Pittsburgh Healthcare System. Participants will additionally continue any previously prescribed pharmacotherapy for substance use and/or other mental health conditions, if applicable.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment As Usual Outpatient Substance Use Treatment
Description: All participants will receive treatment as usual outpatient substance use services during the 12-week treatment interval. TAU will specifically entail recommended participation in at least two outpatient group and/or individual psychotherapy encounters per week within the Center for Treatment of Addictive Disorders (CTAD) at VA Pittsburgh Healthcare System. Participants will additionally continue any previously prescribed pharmacotherapy for substance use and/or other mental health conditions, if applicable.
Study: NCT02077868

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Maintenance
Description: Usual maintenance therapy according to local investigator's practice, e.g. treatment break, reduced treatment, continued treatment, and other

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGN1703 treatment
Description: MGN1703 will be used as single agent maintenance treatment
Study: NCT02730832

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires completed at D0
Study: NCT00854581

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEG-interferon alfa-2b
Description: Administered subcutaneously.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Interferon alfa-2b
Description: Administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic Acid
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zidovudine
Description: Administered intravenously during Induction Therapy; orally during Maintenance Therapy in all Phases (1, 2A and 2B).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zidovudine
Description: Administered intravenously during Induction Therapy; orally during Maintenance Therapy in all Phases (1, 2A and 2B).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zidovudine
Description: Administered intravenously during Induction Therapy; orally during Maintenance Therapy in all Phases (1, 2A and 2B).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zidovudine
Description: Administered intravenously during Induction Therapy; orally during Maintenance Therapy in all Phases (1, 2A and 2B).
Study: NCT02242357

Intervention type: DRUG
Intervention: Micardis®

Intervention type: DRUG
Intervention: Micardis® Plus
Study: NCT04106310

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High-flux dialyzer
Description: a dialyzer meeting the definition of high-flux
Study: NCT02053636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lucitanib
Study: NCT02730832

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires completed at D15 (test-retest for 30 patients)
Study: NCT04731740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Investigators' choice
Study: NCT04329156

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digitally Flip Technique
Description: A prefabricated shell will be made then after implant placement, the shell will be attached to a plastic abutment using flowable composite to make a customized healing abutment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stock Healing Abutment
Description: After implant placement, a stock healing abutment will be placed onto the implant and screwed on. It will be selected to be 1-2 mm above the gingival margin and slightly smaller in diameter than the intended final restoration.
Study: NCT03737357

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SLActive® implant
Description: One study test (SLActive® surface) (and simultaneously, in a split-mouth design one study control (SLA® surface) implant (Bone Level Tapered, Roxolid®)) will be placed in two different quadrants of partially edentulous patients. The implants will be placed at premolars, molars and canine positions in the mandible and maxilla (healed extraction sites). Implants will be restored with a single crown or splinted restorations 8 weeks after implant placement.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SLA® implant
Description: One study test (SLActive® surface) (and simultaneously, in a split-mouth design one study control (SLA® surface) implant (Bone Level Tapered, Roxolid®)) will be placed in two different quadrants of partially edentulous patients. The implants will be placed at premolars, molars and canine positions in the mandible and maxilla (healed extraction sites). Implants will be restored with a single crown or splinted restorations 8 weeks after implant placement.
Study: NCT02184988

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum purified neurotoxin, Type A
Description: The subject is to be injected intra-muscularly into a total of five sites: the mid-line of the procures muscle, the inferomedial aspect of each corrugator muscle and the superior middle aspect of each corrugator, at least 1 cm above the bony orbital rim. Each site is injected with 0.1 ml (4U), for a total of 20 U and 0.5 ml.
Study: NCT00594009

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Venovenous CO2 Removal (VVCO2R) in COPD
Description: Patients who meet criteria will be placed on an extracorporeal circuit consisting of an oxygenator, centrifugal pump, tubing and indwelling double lumen venous catheter for CO2 removal for up to 96 hours for treatment of COPD exacerbation requiring hospitalization and intensive care
Study: NCT01573988

Intervention type: OTHER
Group type: OTHER
Intervention: Increasing eating frequency
Description: The subjects receive the same breakfast with two sequences :~* breakfast in one intake at 8:00~* breakfast in four isocaloric intakes (8:00, 9:00, 10:00, 11:00) The sequence made twice : one for metabolic study and one for the study of eating behavior~The lunch during metabolic study is a standard meal The lunch during behavioural study is an ad libitum buffet test meal.~The administration order is determined by randomized allocation. The wash-out period is one to three weeks.~There are not diet or exercise interventions.

Intervention type: OTHER
Group type: OTHER
Intervention: Increasing eating frequency
Description: The subjects receive the same breakfast with two sequences :~* breakfast in one intake at 8:00~* breakfast in four isocaloric intakes (8:00, 9:00, 10:00, 11:00) The sequence made twice : one for metabolic study and one for the study of eating behavior~The lunch during metabolic study is a standard meal The lunch during behavioural study is an ad libitum buffet test meal.~The administration order is determined by randomized allocation. The wash-out period is one to three weeks.~There are not diet or exercise interventions.
Study: NCT02946515

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: The educational intervention will be the online simulation training program. Participants will be taught how to use the simulation during a 30 minute orientation session with a research staff person. We will use a mastery based approach rather than prescribing an absolute number of hours participants need to play. The criteria are as follows: 1) achieving a score of 90% or more on 2 out of the last 3 simulations played or 2) maximum of 8 hours of play, whichever comes first. After the orientation sessions, training sessions will be completed by participants on their own. The research team will confirm remote usage, and contact participants by email and phone to prompt usage as needed. The research team anticipates that the proposed method will accommodate for participant schedules while still ensuring intervention compliance.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wait List Control
Description: Access to the online simulation training after the follow-up measurement visit is complete
Study: NCT01315158

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol Alone
Description: Recommended Propofol doses before considering crossover:~* Induction: 2-2.5 mg/kg~* Maintenance: 0.1-0.2 mg/kg/min

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol+Benzo/Opioids
Description: 1. Recommended Versed:~   a. Prior to intubation~  * patient is \< 50 kg = 1 mg Versed~  * patient is 50-75 kg = 1.5 mg Versed~  * patient is \> 75 kg = 2 mg Versed~2. Recommended Fentanyl~   1. Prior to intubation = 0.5 ug/kg~  2. Total procedural dose = 1 ug/kg